Scancell Holdings plc (LON:SCLP – Get Free Report) shares hit a new 52-week high on Monday . The company traded as high as GBX 25.50 and last traded at GBX 25, with a volume of 8427769 shares. The stock had previously closed at GBX 22.77.
Scancell Price Performance
The stock has a 50 day moving average of GBX 14.07 and a two-hundred day moving average of GBX 12.26. The stock has a market cap of £217.62 million, a PE ratio of -38.13 and a beta of 0.57. The company has a debt-to-equity ratio of -193.29, a quick ratio of 13.01 and a current ratio of 0.56.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
See Also
- Five stocks we like better than Scancell
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
